Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.150
+0.060 (2.87%)
At close: May 12, 2025, 4:00 PM
2.189
+0.039 (1.83%)
After-hours: May 12, 2025, 7:25 PM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $3.08M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $10.96M. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$10.96M
Revenue Growth
n/a
P/S Ratio
56.97
Revenue / Employee
$49,805
Employees
220
Market Cap
731.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NUVB News
- 3 hours ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 21 hours ago - Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 days ago - Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes - Seeking Alpha
- 11 days ago - Nuvation Bio to Present at The Citizens Life Sciences Conference - Business Wire
- 20 days ago - Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 - Business Wire
- 5 weeks ago - Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference - Business Wire
- 6 weeks ago - Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 - Business Wire